Clear-cut therapeutic targets for NSCLC include epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase, mesenchymal epidermal conversion factor, and human epidermal growth factor receptor (HER), as well as vascular endothelial growth factor, monoclonal antibodies, and multi-targeted small molecule inhibitors. Here, EGFR is linked to non-small cell lung carcinoma.